Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine
- PMID: 36270334
- PMCID: PMC9578965
- DOI: 10.1053/j.gastro.2022.10.010
Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine
Figures

References
-
- Kennedy NA, Janjua M, et al. Gut. Published July 28, 2022. https://doi.org/10.1136/gutjnl-2022-327570. - DOI
Supplementary References
-
- Kennedy N.A., Goodhand J.R., et al. Gut. 2021;70:865–875. - PubMed
-
- Kennedy NA, Janjua M, et al. Gut. Published July 28, 2022. https://doi.org/10.1136/gutjnl-2022-327570. - DOI
-
- Lin S.M., Kennedy N.A., Saifuddin A., Sandoval D.M., et al. Nat Commun. 2022;13:1379–1392. - PubMed
-
- Pollock K.M., et al. EClinicalMedicine. 2022;44
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
- COV-LT2-0027/DH_/Department of Health/United Kingdom
- BRC-1215-20014/DH_/Department of Health/United Kingdom
- MR/R02622X/1/MRC_/Medical Research Council/United Kingdom
- NIHR134607/DH_/Department of Health/United Kingdom
- MR/W024977/1/MRC_/Medical Research Council/United Kingdom
- MR/S019553/1/MRC_/Medical Research Council/United Kingdom
- CL-2019-21-502/DH_/Department of Health/United Kingdom
- MR/W020610/1/MRC_/Medical Research Council/United Kingdom
- MR/V036939/1/MRC_/Medical Research Council/United Kingdom
- 220725/Z/20/Z/WT_/Wellcome Trust/United Kingdom
- MR/S034919/1/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous